2024

Journal Articles- Refereed

M Vu, K Degeling, GL Ryland, O Hofmann, AP Ng, D Westerman, MJ Ijzerman. Economic Impact of Whole Genome Sequencing and Whole Transcriptome Sequencing Versus Routine Diagnostic Molecular Testing to Stratify Patients with B-Cell Acute Lymphoblastic Leukemia. The Journal of Molecular Diagnostics 26 (8), 673-684

M Vu, K Degeling, D Westerman, MJ Ijzerman. Scenario analysis and multi-criteria decision analysis to explore alternative reimbursement pathways for whole genome sequencing for blood cancer patients. Journal of Cancer Policy, 100501

K Degeling, YH To, K Trapani, S Athan, P Gibbs, MJ IJzerman, F Franchini. Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Line in Australia. Value in Health 2024/7/6

G Chazan, F Franchini, R Shah, M Alexander, A John, M IJzerman, ...Real World Treatment and Outcomes in ALK-rearranged Non-small Cell Lung Cancer; Results from a Large US-based Database. JTO Clinical and Research Reports, 100662

HA Khorshidi, D Marshall, I Goranitis, B Schroeder, M IJzerman. System dynamics simulation for evaluating implementation strategies of genomic sequencing: tutorial and conceptual model. Expert Review of Pharmacoeconomics & Outcomes Research 24 (1), 37-47

M Vu, K Degeling, ER Thompson, P Blombery, D Westerman, M IJzerman. Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia. Applied health economics and health policy 22 (1), 107-122